Best known globally for its aspirin and locally for its life-saving hemophilia treatments, drug giant Bayer is firming up plans to lead one of biotech's hottest areas with a pioneering new cell therapy manufacturing facility on its fast-changing Berkeley campus.
The moves come as Bayer seeks approval from Berkeley leaders for a new 30-year master plan that would allow the Germany-based company to build 1 million square feet of production, research and office space and add some 1,000 employees over that period.
At the forefront of Bayer's big plans are cell therapies, which employ genetically engineered cells to fix blood cancers and potentially more diseases, and one-shot-and-done gene therapies that insert a correct copy of a gene to replace a defective, disease-causing gene.
Dean Phillips campaign event, 1/17/24; image by
Artaxerxes, CC BY-SA 4.0, via Wikimedia Commons
Political rookies are rarely elected President. The big exception was the one-termer who is currently trying again, and even he ran an essentially conventional campaign. But the modern masters of technology pride themselves on disrupting hide-bound, old-fashioned industries. And what is presidential politics if not an old-fashioned industry?
We are shocked, shocked to report that AI and its makers are sidling into the race for...
Say you’re about to start in vitro fertilization and your clinic offers you a futuristic new option: It can analyze the DNA of the embryos you conceive and let you choose which one to implant based on their genes.
By Rebecca Carballo , The New York Times | 12.04.2023
Hackers, using old passwords from customers of the genetic testing company 23andMe, were able to gain access to personal information from about 6.9 million profiles, which in some cases included ancestry trees, birth years and geographic locations, the company said...